-
2022-500721-32-00
4
AML and MDS patients failing or being refractory to hypomethylating ag
-
2022-501463-40-00
5
Locally Advanced or Metastatic Cholangiocarcinoma
-
2024-517339-30-00
7
Advanced Solid Tumors
-
2025-522618-22-00
5
Treatment of moderate to severe glabellar lines
-
2025-523672-23-00
4
Metastatic Castrate Sensitive Prostate Cancer - mCSPC
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-500479-29-00
10
2023-03-28
International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
-
2022-500609-42-00
4
2023-02-24
Anemia Due to Lower-Risk Myelodysplastic Syndromes
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2024-517167-23-00
5
2025-08-28
Chronic Hepatitis D Infection
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-507111-35-00
9
2024-06-03
Prostate Cancer
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2024-512782-14-00
7
2024-03-20
Treatment of Moderate to Severe Upper Facial Lines
-
2024-516504-42-00
5
2022-03-05
Respiratory distress syndrome in preterm infants
-
2024-513723-16-00
4
2021-10-21
metastatic colorectal cancer
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-503383-17-01
5
2024-10-10
Female androgenetic alopecia